Attenuated methamphetamine induced neurotoxicity by modafinil administration in mice

Synapse

Volumn 65, Issue 10, 2011, Pages 1087-1098

  Raineri, Mariana ^a   Peskin, Viviana ^a   Goitia, Belén ^b   Taravini, Irene R E ^a   Giorgeri, Sergio ^c   Urbano, Francisco J ^b   Bisagno, Verónica ^a  

^a Instituto de Investigaciones Farmacologicas   (Argentina)

^b Biología Molecular y Neurociencias ^*  (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Behavior; Dopamine (DA); Modafinil; Neurotoxicity

Indexed keywords

DOPAMINE; METHAMPHETAMINE; MODAFINIL; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG EFFICACY; LOCOMOTION; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STEREOTYPY; TREATMENT OUTCOME;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; MALE; METHAMPHETAMINE; MICE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; STEREOTYPED BEHAVIOR;

EID: 79960964501     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20943     Document Type: Article

References (33)

1. Achat-Mendes C, Ali SF, Itzhak Y. 2005. Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice. Neuropsychopharmacology 30: 1128-1137.
2. Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A, Smith EV, Kahn R, Chiang N, Vocci F, Ciraulo D, Dackis C, Roache JD, Salloum IM, Somoza E, Urschel HCIII, Elkashef AM. 2009. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 104(1-2): 133-139.
3. Ballon JF, Feifel D. 2006. A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatry 67: 554-566.
4. Beck P, Odle A, Wallace-Huitt T, Skinner RD, Garcia-Rill E. 2008. Modafinil increases arousal determined by P13 potential amplitude: An effect blocked by gap junction antagonists. Sleep 31: 1647-1654.
5. Berridge CW. 2006. Neural substrates of psychostimulant-induced arousal. Neuropsychopharmacology 11: 2332-2340. Epub 2006 Jul 19.
6. Bisagno V, Ferguson D, Luine VN. 2002. Short toxic methamphetamine schedule impairs object recognition task in male rats. Brain Research 940: 95-101.
7. Chartoff EH, Marck BT, Matsumoto AM, Dorsa DM, Palmiter RD. 2001. Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation. Proc Natl Acad Sci USA 98: 10451-10456.
8. Creese I, Iversen SD. 1973. Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Brain Res 55: 369-382.
9. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. 2005. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30: 205-211.
10. Davidson C, Gow AJ, Lee TH, Ellinwood EH. 2001. Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36: 1-22.
11. Fog JU, Khoshbouei H, Holy M, Owens WA, Vaegter CB, Sen N, Nikandrova Y, Bowton E, McMahon DG, Colbran RJ, Daws LC, Sitte HH, Javitch JA, Galli A, Gether U. 2006. Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51: 417-429.
12. Garcia-Rill E, Heister DS, Ye M, Charlesworth A, Hayar A. 2007. Electrical coupling: Novel mechanism for sleep-wake control. Sleep 30: 1405-1414. Subject of an Editorial.
13. Ghahremani DG, Tabibnia G, Monterosso J, Hellemann G, Poldrack RA, London ED. 2011. Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals. Neuropsychopharmacology 36: 950-959.
14. Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW. 2008. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 33: 761-768.
15. Kalechstein AD, De La Garza R2nd, Newton TF. 2010. Modafinil administration improves working memory in methamphetamine-dependent individuals who demonstrate baseline impairment. Am J Addict 19: 340-344.
16. Kelly PH, Iversen SD. 1976. Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: Abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol 40: 45-56.
17. Myrick H, Malcolm R, Taylor B, LaRowe S. 2004. Modafinil: Preclinical, clinical, and post-marketing surveillance-A review of abuse liability issues. Ann Clin Psychiatry 16: 101-109.
18. Padmanabhan S, Lambert NA, Prasad BM. 2008. Activity-dependent regulation of the dopamine transporter is mediated by Ca(2+)/calmodulin-dependent protein kinase signaling. Eur J Neurosci 28: 2017-2027.
19. Paxinos G, Franklin KBJ. 2001. The mouse brain in stereotaxic coordinates, 2nd ed. London: Academic.
20. Picconi B, Gardoni F, Centonze D, Mauceri D, Cenci MA, Bernardi G, Calabresi P, Di Luca M. 2004., Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci 24(23): 5283-5291.
21. Pu C, Fisher JE, Cappon GD, Vorhees CV. 1994. The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum. Brain Res 649(1-2): 217-224.
22. Reichel CM, See RE. 2010. Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse. Psychopharmacology (Berl) 210: 337-346.
23. Ridley RM. 1994. The psychology of perserverative and stereotyped behaviour. Prog Neurobiol 44: 221-231.
24. Robinson TE, Becker JB. 1986. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Res 396: 157-198.
25. Schmidt CJ, Gibb JW. 1985. Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: Effects of amfonelic acid. Eur J Pharmacol 109: 73-80.
26. Segal DS, Kuczenski R. 1997. Repeated binge exposures to amphetamine and methamphetamine: Behavioral and neurochemical characterization. J Pharmacol Exp Ther 282: 561-573.
27. Suemaru J, Akiyama K, Tanabe Y, Kuroda S. 2000. Methamphetamine decreases calcium-calmodulin dependent protein kinase II activity in discrete rat brain regions. Synapse 36: 155-166.
28. Thomas DM, Francescutti-Verbeem DM, Kuhn DM. 2008. The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J Neurochem 105: 605-616.
29. van Vliet SA, Blezer EL, Jongsma MJ, Vanwersch RA, Olivier B, Philippens IH. 2008. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy. Brain Res 16;1189: 219-228.
30. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, Wang GJ, Jayne M, Hooker JM, Wong C, Hubbard B, Carter P, Warner D, King P, Shea C, Xu Y, Muench L, Apelskog-Torres K. 2009. Effects of modafinil on dopamine and dopamine transporters in the male human brain: Clinical implications. JAMA 301: 1148-1154.
31. Volz TJ, Hanson GR, Fleckenstein AE. 2007. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. J Neurochem 101: 883-888.
32. Urbano FJ, Leznik E, Llinás RR. 2007. Modafinil enhances thalamocortical activity by increasing neuronal electrotonic coupling. Proc Natl Acad Sci USA 104: 12554-12559.
33. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, Prisinzano TE, Baumann MH. 2009. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 329: 738-746.